Abbott
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world - in nutrition, diagnostics, medical devices and branded generic pharmaceuticals - that create more possibilities for more people at all stages of life. Today, 73,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
Business & Industry
- Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures
- APRINOIA Therapeutics awarded grant from The Michael J. Fox Foundation for Parkinson's Research
- Novartis phase II data for new inhaled combination treatment (QVM149) demonstrates significant improvements over current standard-of-care inhaled treatment
- New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
- Roche's personalised medicine entrectinib shrank tumours harbouring NTRK, ROS1 or ALK gene fusions in children and adolescents
Research & Development
- Aspirin green light for brain bleed stroke patients, study finds
- Benralizumab not effective reducing exacerbations in moderate to very severe COPD
- Cancer drug could be repurposed to provide treatment for brain aneurysms
- Bone cells suppress cancer metastases
- Genetic therapy heals damage caused by heart attack
- Researchers define Alzheimer's-like brain disorder
- Possible link between autism and antidepressants use during pregnancy
Conferences & Events
- Highly Potent Active Pharmaceutical Ingredients USA (HPAPI) Conference
- Wearable Injectors and Connected Devices Conference 2019
- Researchers block protein that plays a key role in Alzheimer's disease
- Highly Potent APIs 2019 Conference
- SMi's 9th Annual Conference: Biobanking 2019
- Last call for registrations to Pre-Filled Syringes East Coast conference
- Exclusive speaker interview with SCHOTT Pharmaceutical Systems released for Pre-Filled Syringes East Coast 2019
Regulatory Affairs
- FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
- FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome
- FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
- FDA approves first treatment for pediatric patients with lupus
- FDA permits marketing of first medical device for treatment of ADHD